國家衛生研究院 NHRI:Item 3990099045/1131
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855490      在线人数 : 1150
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于NHRI管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/1131


    题名: Synthesis and anticancer evaluation of vitamin K-3 analogues
    作者: Chen, CP;Liu, YZ;Shia, KS;Tseng, HY
    贡献者: Division of Biotechnology and Pharmaceutical Research
    摘要: Novel vitamin K-3 analogues were synthesized and evaluated for their anticancer activity. Compound 6, 9, 10, 11, 14, and (+/-)15 demonstrated a strong inhibitory activity against the tumor cells of A-549, Hep G2, MCF7, MES-SA, MES-SA/Dx5, MKN45, SW-480, and TW-039. Compound (+/-)15 displayed potent tumor cell cytotoxicity, and compound 14 selectively affected MCF7, even though it did not influence normal cells Detroit551 and WI-38. Compound (+/-)15 inhibited MES-SA and MES-SA/Dx5, and this specific result shows that compound (+/-)15 may become a good anticancer drug candidate. (C) 2002 Elsevier Science Ltd. All rights reserved.
    关键词: Chemistry, Medicinal;Chemistry, Organic
    日期: 2002-10-07
    關聯: Bioorganic and Medicinal Chemistry Letters. 2002 Oct;12(19):2729-2732.
    Link to: http://dx.doi.org/10.1016/S0960-894X(02)00532-2
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0960-894X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000178115700015
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0037037395
    显示于类别:[夏克山] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    000178115700015.pdf102KbAdobe PDF653检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈